195 related articles for article (PubMed ID: 22270713)
1. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients.
Schilling B; Halstead ES; Schuler P; Harasymczuk M; Egan JE; Whiteside TL
Cancer Immunol Immunother; 2012 Sep; 61(9):1395-405. PubMed ID: 22270713
[TBL] [Abstract][Full Text] [Related]
2. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions.
Garcia-Iglesias T; Del Toro-Arreola A; Albarran-Somoza B; Del Toro-Arreola S; Sanchez-Hernandez PE; Ramirez-Dueñas MG; Balderas-Peña LM; Bravo-Cuellar A; Ortiz-Lazareno PC; Daneri-Navarro A
BMC Cancer; 2009 Jun; 9():186. PubMed ID: 19531227
[TBL] [Abstract][Full Text] [Related]
3. In-vitro IL-2 or IFN-α-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients.
Konjević G; Mirjačić Martinović K; Vuletić A; Babović N
Melanoma Res; 2010 Dec; 20(6):459-67. PubMed ID: 20938360
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Expression of Surface Receptors on NK Cells and NKG2D on Immunocytes in Peripheral Blood of Patients with Nasopharyngeal Carcinoma.
Xu Y; Zhou R; Huang C; Zhang M; Li J; Zong J; Qiu S; Lin S; Chen H; Ye Y; Pan J
Asian Pac J Cancer Prev; 2018 Mar; 19(3):661-665. PubMed ID: 29580037
[TBL] [Abstract][Full Text] [Related]
5. Effect of cytokines on NK cell activity and activating receptor expression in high-risk cutaneous melanoma patients.
Martinović KM; Milićević M; Larsen AK; Džodić R; Jurišić V; Konjević G; Vuletić A
Eur Cytokine Netw; 2019 Dec; 30(4):160-167. PubMed ID: 32096478
[TBL] [Abstract][Full Text] [Related]
6. NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.
Vacca P; Martini S; Garelli V; Passalacqua G; Moretta L; Mingari MC
Eur J Immunol; 2013 Feb; 43(2):550-61. PubMed ID: 23192659
[TBL] [Abstract][Full Text] [Related]
7. Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells.
Boerman GH; van Ostaijen-ten Dam MM; Kraal KC; Santos SJ; Ball LM; Lankester AC; Schilham MW; Egeler RM; van Tol MJ
Cancer Immunol Immunother; 2015 May; 64(5):573-83. PubMed ID: 25854581
[TBL] [Abstract][Full Text] [Related]
8. Effects of micro environmental factors on natural killer activity (NK) of beta thalassemia major patients.
Atasever Arslan B; Erdem-Kuruca S; Karakas Z; Erman B; Ergen A
Cell Immunol; 2013 Apr; 282(2):93-9. PubMed ID: 23770717
[TBL] [Abstract][Full Text] [Related]
9. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
10. Phenotypic and functional characteristics of blood natural killer cells from melanoma patients at different clinical stages.
Fregni G; Messaoudene M; Fourmentraux-Neves E; Mazouz-Dorval S; Chanal J; Maubec E; Marinho E; Scheer-Senyarich I; Cremer I; Avril MF; Caignard A
PLoS One; 2013; 8(10):e76928. PubMed ID: 24204708
[TBL] [Abstract][Full Text] [Related]
11. Novel aspects of in vitro IL-2 or IFN-α enhanced NK cytotoxicity of healthy individuals based on NKG2D and CD161 NK cell receptor induction.
Konjević G; Mirjačić Martinović K; Vuletić A; Radenković S
Biomed Pharmacother; 2010 Dec; 64(10):663-71. PubMed ID: 20800424
[TBL] [Abstract][Full Text] [Related]
12. Impairment in cytotoxicity and expression of NK cell- activating receptors on human NK cells following exposure to asbestos fibers.
Nishimura Y; Miura Y; Maeda M; Kumagai N; Murakami S; Hayashi H; Fukuoka K; Nakano T; Otsuki T
Int J Immunopathol Pharmacol; 2009; 22(3):579-90. PubMed ID: 19822075
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells.
Castriconi R; Cantoni C; Della Chiesa M; Vitale M; Marcenaro E; Conte R; Biassoni R; Bottino C; Moretta L; Moretta A
Proc Natl Acad Sci U S A; 2003 Apr; 100(7):4120-5. PubMed ID: 12646700
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines.
Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE
Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients.
Bose A; Chakraborty T; Chakraborty K; Pal S; Baral R
Cancer Immun; 2008 Jun; 8():10. PubMed ID: 18547033
[TBL] [Abstract][Full Text] [Related]
16. Influence of in vitro IL-2 or IL-15 alone or in combination with Hsp-70-derived 14-mer peptide (TKD) on the expression of NK cell activatory and inhibitory receptors.
Hromadnikova I; Pirkova P; Sedlackova L
Mediators Inflamm; 2013; 2013():405295. PubMed ID: 23476104
[TBL] [Abstract][Full Text] [Related]
17. Expressions of natural cytotoxicity receptor, NKG2D and NKG2D ligands in endometriosis.
Xu H
J Reprod Immunol; 2019 Nov; 136():102615. PubMed ID: 31655348
[TBL] [Abstract][Full Text] [Related]
18. IFNalpha2b stimulated release of IFNgamma differentially regulates T cell and NK cell mediated tumor cell cytotoxicity.
Bose A; Baral R
Immunol Lett; 2007 Jan; 108(1):68-77. PubMed ID: 17112599
[TBL] [Abstract][Full Text] [Related]
19. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells.
Schilling B; Harasymczuk M; Schuler P; Egan J; Ferrone S; Whiteside TL
PLoS One; 2013; 8(2):e47234. PubMed ID: 23408925
[TBL] [Abstract][Full Text] [Related]
20. Expression of NKp30, NKp46 and DNAM-1 activating receptors on resting and IL-2 activated NK cells from healthy donors according to CMV-serostatus and age.
Campos C; López N; Pera A; Gordillo JJ; Hassouneh F; Tarazona R; Solana R
Biogerontology; 2015 Oct; 16(5):671-83. PubMed ID: 25991472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
